亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Scalable Lipid Bilayer Microfluidics for High-Throughput Gene Editing

技術優勢
Efficient High-throughput No clogging or biofouling Long-term use
技術應用
Gene editing (stem cells, immunotherapy, research tools) Introducing large biomolecules into cells
詳細技術說明
Researchers led by Paul Weiss from the Departments of Chemistry & Biochemistry and Pediatrics have created a new microfluidic device for high-throughput gene editing of cells. Typical microfluidic devices have a throughput of 20,000 cells per second, but they break after passing 1 million cells due to clogging. These researchers have found a way to line the microfluidic device with a lipid bilayer to prevent cell adhesion to the fluidic device and circumvent the issue of clogging. Furthermore, this method is compatible with many different materials from which microfluidic devices are made and allows for chemical modification of the bilayer to influence cell behavior. Compared to conventional electroporation, these microfluidic devices can introduce larger DNA fragments (e.g., bacterial DNA) into cells and use less processing steps, with higher throughput, which would save hours on certain medical procedures.
*Abstract
Researchers led by Paul Weiss from the Department of Chemistry and Pediatrics at UCLA have created a new microfluidic device for high-throughput gene editing of cells.
*Principal Investigation

Name: Jason Belling

Department:


Name: Nam-Joon Cho

Department:


Name: Joshua Jackman

Department:


Name: Steven Jonas

Department:


Name: Paul Weiss

Department:

其他

Background

Gene editing has many potential applications, allowing for the modification of immune cells to target cancers and the modification of stem cells to treat various diseases. Current gene-editing techniques use viruses to modify DNA; however, a new technique known as CRISPR/Cas9 has gained popularity in genetic engineering due to its efficiency and precision. To introduce CRISPR/Cas9 into cells, electroporation is used to create tiny pores in the cells for the genetic modifiers to enter through. Unfortunately, electroporation is inefficient, expensive, and creates problems with cell toxicity. Microfluidics present a more efficient option to create these pores for entry by squeezing cells through tiny channels that temporarily introduces pores due to cell stress, but these techniques suffer from short shelf lives due to clogging and biofouling.


Additional Technologies by these Inventors


Tech ID/UC Case

29497/2018-437-0


Related Cases

2018-437-0

國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備